IRIXIRIXHealthcare · Medical Devices

IRIX Stock Forecast: IRIDEX Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.44
−5.34% on the day

The median 12-month analyst price target for IRIDEX Corp. is $2. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$8.3M
Ticker Nerd rank
47/ 100
Median analyst target
$2.00
Analysts covering
1
Revenue$12.6M−7.4% y/y
Operating income−$1.0M
Net income−$1.3M
Free cash flow$124K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−35.5%
1M
−41.5%
YTD
−61.0%
1Y
−52.7%
From 52W high
−71.5%
From 52W low
0.0%
$0.44
$1.56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores IRIDEX Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
47/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
74
Quality
68
Growth
54
Momentum
49
Accruals
42
Volatility
34
Revisions
27
Issuance
19

Value (74): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IRIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IRIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26IRIXHigh $2.00Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$2.00
Low
$2.00
Median
$2.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2024StifelMaintainsHold$2.00
26 Aug 2022StifelDowngradeHold—
12 May 2021Roth CapitalMaintainsBuy—
3 Mar 2021Roth CapitalMaintainsBuy—
13 Jan 2021Roth CapitalMaintainsBuy—
12 May 2020StifelMaintainsBuy—
4 Jan 2019StifelMaintainsBuy—
4 Jan 2019Stifel NicolausMaintainsBuy—
26 Oct 2018StifelInitiatesBuy—
26 Oct 2018Stifel NicolausInitiatesBuy—
21 Dec 2016Roth CapitalInitiatesBuy—
26 Jan 2016Singular ResearchInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IRIX.

Market Radar

This page is one stock. Monday covers all of them.

IRIX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IRIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, IRIDEX Corp. returned −52.7% against +6.9% for the S&P 500, dividends included.

IRIX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160180Jan 26Apr 26Jul 26Oct 26IRIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IRIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.2×

Cheaper than 92% of US stocks

Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
34.2%

Higher than 41% of US stocks

Operating margin
−5.1%

Higher than 30% of US stocks

Net margin
−6.9%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−92.4%

Higher than 14% of US stocks

Return on assets
−5.5%

Higher than 32% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IRIDEX Corp. has a market value of $8.3M and an enterprise value of $18.0M.

  • Revenue in the twelve months to 30 June 2026: $51.6M. The latest quarter shrank 7.4% year on year.

  • Net income over the same four quarters: −$3.5M, a −6.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.20.

  • Free cash flow in the twelve months to 30 June 2026: −$2.0M.

  • Shares outstanding: 17.4M.

  • IRIDEX Corp. employs 93 people — $555K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

IRIX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
IRIXIRIDEX Corp.$8.3M47
LFWDLifeward Ltd.$7.9M15
SINTSINTX Technologies, Inc.$8.3M41
AEMDAethlon Medical, Inc.$8.8M24
PAVMPAVmed, Inc.$9.1M31
ARAYAccuray, Inc.$6.2M46
NMTCNeuroOne Medical Technologies Corp.$5.9M36

Take a look at IRIX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own IRIDEX Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IRIX

What is the IRIX stock price forecast for 2026-2027?

The median 12-month analyst price target for IRIDEX Corp. is $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IRIX stock a buy right now?

Of the 1 analyst covering IRIDEX Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRIDEX Corp. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IRIX?

As at 21 Nov 2026, IRIDEX Corp. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (74 of 100).

Will IRIX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $2, and Ticker Nerd's factor model ranks IRIDEX Corp. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IRIX stock forecast for 2030?

No analyst covering IRIDEX Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has IRIX stock performed over the past year?

IRIDEX Corp. returned -52.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IRIDEX Corp. do?

Iridex Corp. is an ophthalmic medical technology company that develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for eye care professionals. The company’s products are used in the treatment of glaucoma, retinal disorders, diabetic eye disease, and other sight-threatening conditions, supporting both office-based procedures and surgical settings.

Company

About IRIDEX Corp.

Iridex Corp. is an ophthalmic medical technology company that develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for eye care professionals. The company’s products are used in the treatment of glaucoma, retinal disorders, diabetic eye disease, and other sight-threatening conditions, supporting both office-based procedures and surgical settings. Iridex’s portfolio includes laser consoles, delivery platforms, and single-use probes designed to work with its proprietary MicroPulse technology and other treatment systems. The company serves ophthalmologists, hospitals, surgical centers, research institutions, veterinary practices, and clinics through direct sales in the United States and distributor networks internationally. Headquartered in Mountain View, California, and founded in 1989, Iridex plays a specialized role in the medical device market by providing tools focused on precision ophthalmic therapy and recurring consumable use.

CEO Mr. Patrick Mercer · 93 employees · United States · https://www.iridex.com